Table 1.

Time between completion of neoadjuvant therapy and first reassessment in watch and wait clinical studies

Study	Patients (n)	Neoadyuvant therapy		Timing of assessment after CRT
		Radiotherapy schedule	Chemotherapy regimen
Habr-Gama et al[107], 2013	70	54Gy/30	CRT: 5-FU/LV CNCT: 5-FU/LV x3	10 wk
Araujo et al[128], 2015	51	45 Gy/25 or 50, 40 Gy/28	CRT: 5-FU or capecitabine	NS
Smith et al[129], 2012	32	50,4 Gy/28	CRT: 5-FU or capecitabine	4-10 wk
Dalton et al[127], 2012	12	45 Gy/25	CRT: capecitabine	8 wk
Renehan et al[99], 2016	259	45 Gy/25	CRT: 5-FU or capecitabine	≥ 8 wk
Appelt et al[5], 2015	51	60 Gy/30 to tumor + 50 Gy/30 to LNs	Tegafur-uracil (UFT)	6 wk
Vaccaro et al[130], 2016	204	50.4 Gy/28	CRT: 5-FU/LV	8-12 wk
Lai et al[131], 2016	267	45 Gy/25 or 54 Gy/30	CRT: 5-FU/LV	8-12 wk
Martens et al[98], 2016	141	50.4 Gy/28 or 5 Gy/5	CRT: 5-FU	8-20 wk
Creavin et al[132],	362	50-54 Gy/30	CRT: 5-FU	6-8 wk

CRT: Chemoradiation therapy; CNCT: Consolidation chemotherapy; NS: Not stated; 5-FU: 5-fluorouracil; LV: Leucovorin.